Moderna, Inc.
Financials
Valuation Metrics
Moderna, Inc.'s Market Cap is $21.87B. At end of 2025 it was $11.56B. Ranked #582 of 3,112 in US market (top 19%), #178 of 1,445 on NASDAQ (top 12%), #28 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 10%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $21.87B | US#582/3,112 Sec#28/269 |
| Revenue | $2.23B | US#1,414/3,112 Sec#41/269 |
| Net Income | $-3.19B | US—/3,112 Sec—/269 |
| Total Assets | $11.49B | US#908/3,112 Sec#28/269 |
| Net Assets | $7.41B | US#538/3,112 Sec#22/269 |
| Employees | 4,700 | US#865/3,112 Sec#20/269 |
| Value | ||
| P/B | 2.95x | US#1,655/3,112 Sec#86/269 |
| P/S | 9.83x | US#2,646/3,112 Sec#119/269 |
| FCF Yield | -7.23% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -43.12% | US#2,707/3,112 Sec#160/269 |
| ROA | -27.80% | US#2,854/3,112 Sec#156/269 |
| Op. Margin | -153.35% | US#2,843/3,112 Sec#131/269 |
| Revenue Growth | 263.55% | US#54/3,112 Sec#17/269 |
| Financial Health | ||
| Debt Ratio | 55.08% | US#625/3,112 Sec#145/269 |
| Total Debt | $1.30B | US#1,345/3,112 Sec#36/269 |
| FCF | $-1.58B | US#2,910/3,112 Sec#267/269 |
| Cash | $1.91B | US#438/3,112 Sec#22/269 |
| Current Ratio | 2.41x | US#1,035/3,112 Sec#214/269 |
| Dividend | ||
| Div. Growth | -60.61% | US—/3,112 Sec—/269 |
| Performance | ||
| 1Y Return | 99.64% | US#313/3,112 Sec#82/269 |
| 1M Return | -30.91% | US#3,070/3,112 Sec#257/269 |
| From 52W High | -35.62% | US#2,389/3,112 Sec#183/269 |
| 1Y MDD | -35.51% | US#1,717/3,112 Sec#113/269 |
| Trading | ||
| Volume | 4,386,158 shares | US#426/3,112 Sec#32/269 |
| Trading Value | $242M | US#445/3,112 Sec#22/269 |
| Per Share | ||
| EPS | $-7.20 | US—/3,112 Sec—/269 |
| BPS | $22.07 | US#1,108/3,112 Sec#26/269 |
Company Info
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.